Comparative Pharmacology
Head-to-head clinical analysis: METANDREN versus TESTOSTERONE ENANTHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METANDREN versus TESTOSTERONE ENANTHATE.
METANDREN vs TESTOSTERONE ENANTHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Androgen receptor agonist; binds to androgen receptors in target tissues, activating gene transcription and promoting protein synthesis, growth of male reproductive organs, and secondary sexual characteristics.
Testosterone enanthate is a prodrug of testosterone, which binds to and activates androgen receptors (AR), modulating gene expression and exerting anabolic and androgenic effects. It also exhibits some affinity for estrogen receptors via aromatization.
Oral: 5-25 mg once daily for testosterone replacement therapy in adult males.
50-400 mg intramuscularly every 2-4 weeks
None Documented
None Documented
The terminal elimination half-life of methyltestosterone is approximately 3-4 hours. This short half-life necessitates multiple daily dosing (e.g., 10-50 mg orally 1-3 times daily) to maintain therapeutic androgen levels. However, due to its oral administration and first-pass metabolism, the clinical effect may last longer.
Terminal elimination half-life is approximately 4-5 days (range 3.5-7 days) after intramuscular injection due to slow absorption from the oily depot; supports weekly to biweekly dosing intervals.
Metandren (methyltestosterone) is primarily metabolized in the liver and excreted in the urine as glucuronide and sulfate conjugates. Approximately 90% of a dose is excreted renally, with less than 5% eliminated via feces. Biliary excretion is minimal.
Primarily renal (90% as glucuronide and sulfate conjugates, 6% unchanged) and biliary/fecal (10%).
Category C
Category D/X
Androgen
Androgen